RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024As large corporates reshuffle their portfolios regularly, either as part of ongoing strategic reviews or as part of maturing segments, assets are opportunistically divested and acquired. A growing strategy is emerging around the acquisition of orphan assets as single agents or as part of larger platform portfolios, which reflects in part, ONCY's platform asset in pelareorep for the treatment of multiple cancers. And with a registration ready drug platform, ONCY is now a late-stage clinical development company commanding a significant acquisition valuation over early stage or small molecule companies. Consequently, a premium buy-out/acquisition valuation for ONCY is as close to "world peace" as we can get.